RxDoctor Payments Data

Justin Bottsford-Miller, MD

Gynecologic Oncology · Bozeman, MTNPI 1598986200

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,030 of the $12,912 with a category attached, or 77.7%. Merck accounts for 95.6% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $7,198, more than ten times the $197 reported in 2021.

$12,912in general payments, 2019–2025

Across 50 payments — averaging $258.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$12K
  • GSK$107
  • Genmab U.S., Inc.$99
  • Johnson & Johnson$79
  • AstraZeneca$76
  • Intuitive Surgical$76
  • plus $130 from 5 others
$111,690in research payments, 2019–2025

Across 74 payments — averaging $1509.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Tesaro, Inc.$32K
  • GSK$31K
  • Genentech, Inc.$25K
  • AstraZeneca$13K
  • Merck$9K
  • Incyte Corporation$740
  • plus $203 from 1 others

What the payments were for

  • Speaking & faculty fees$10,03078%
  • Travel & lodging$1,71313%
  • Food & beverage$1,1179%
  • Education$510%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$61,478
Medicare patients
64
Services billed
234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Bozeman

Where these figures come from

Is this you, or does something look wrong? →